1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gastroparesis Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gastroparesis Treatment Market, by Treatment Type
8.1.1. Pharmacological Therapy
8.1.1.1. Market Revenue and Forecast
8.1.2. Device-based Therapy
8.1.2.1. Market Revenue and Forecast
8.1.3. Surgical Treatment
8.1.3.1. Market Revenue and Forecast
8.1.4. Nutritional and Dietary Management
8.1.4.1. Market Revenue and Forecast
9.1. Gastroparesis Treatment Market, by Disease Type
9.1.1. Diabetic Gastroparesis
9.1.1.1. Market Revenue and Forecast
9.1.2. Idiopathic Gastroparesis
9.1.2.1. Market Revenue and Forecast
9.1.3. Post-Surgical Gastroparesis
9.1.3.1. Market Revenue and Forecast
9.1.4. Others (Drug-induced, Neurological disorders, Autoimmune-related)
9.1.4.1. Market Revenue and Forecast
10.1. Gastroparesis Treatment Market, by End User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Specialty Clinics and Gastroenterology Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Ambulatory Surgical Centers (ASCs)
10.1.3.1. Market Revenue and Forecast
10.1.4. Home Care Settings
10.1.4.1. Market Revenue and Forecast
10.1.5. Others (Rehabilitation centers, Long-term care facilities)
10.1.5.1. Market Revenue and Forecast
11.1. Gastroparesis Treatment Market, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast
11.1.4. Others (Direct procurement, Specialty distributors)
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Type
12.1.2. Market Revenue and Forecast, by Disease Type
12.1.3. Market Revenue and Forecast, by End User
12.1.4. Market Revenue and Forecast, by Distribution Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Treatment Type
12.1.5.2. Market Revenue and Forecast, by Disease Type
12.1.5.3. Market Revenue and Forecast, by End User
12.1.5.4. Market Revenue and Forecast, by Distribution Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Treatment Type
12.1.6.2. Market Revenue and Forecast, by Disease Type
12.1.6.3. Market Revenue and Forecast, by End User
12.1.6.4. Market Revenue and Forecast, by Distribution Channel
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Type
12.2.2. Market Revenue and Forecast, by Disease Type
12.2.3. Market Revenue and Forecast, by End User
12.2.4. Market Revenue and Forecast, by Distribution Channel
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Treatment Type
12.2.5.2. Market Revenue and Forecast, by Disease Type
12.2.5.3. Market Revenue and Forecast, by End User
12.2.5.4. Market Revenue and Forecast, by Distribution Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Treatment Type
12.2.6.2. Market Revenue and Forecast, by Disease Type
12.2.6.3. Market Revenue and Forecast, by End User
12.2.6.4. Market Revenue and Forecast, by Distribution Channel
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Treatment Type
12.2.7.2. Market Revenue and Forecast, by Disease Type
12.2.7.3. Market Revenue and Forecast, by End User
12.2.7.4. Market Revenue and Forecast, by Distribution Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Treatment Type
12.2.8.2. Market Revenue and Forecast, by Disease Type
12.2.8.3. Market Revenue and Forecast, by End User
12.2.8.4. Market Revenue and Forecast, by Distribution Channel
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Type
12.3.2. Market Revenue and Forecast, by Disease Type
12.3.3. Market Revenue and Forecast, by End User
12.3.4. Market Revenue and Forecast, by Distribution Channel
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Treatment Type
12.3.5.2. Market Revenue and Forecast, by Disease Type
12.3.5.3. Market Revenue and Forecast, by End User
12.3.5.4. Market Revenue and Forecast, by Distribution Channel
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Treatment Type
12.3.6.2. Market Revenue and Forecast, by Disease Type
12.3.6.3. Market Revenue and Forecast, by End User
12.3.6.4. Market Revenue and Forecast, by Distribution Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Treatment Type
12.3.7.2. Market Revenue and Forecast, by Disease Type
12.3.7.3. Market Revenue and Forecast, by End User
12.3.7.4. Market Revenue and Forecast, by Distribution Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Treatment Type
12.3.8.2. Market Revenue and Forecast, by Disease Type
12.3.8.3. Market Revenue and Forecast, by End User
12.3.8.4. Market Revenue and Forecast, by Distribution Channel
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Type
12.4.2. Market Revenue and Forecast, by Disease Type
12.4.3. Market Revenue and Forecast, by End User
12.4.4. Market Revenue and Forecast, by Distribution Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Treatment Type
12.4.5.2. Market Revenue and Forecast, by Disease Type
12.4.5.3. Market Revenue and Forecast, by End User
12.4.5.4. Market Revenue and Forecast, by Distribution Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Treatment Type
12.4.6.2. Market Revenue and Forecast, by Disease Type
12.4.6.3. Market Revenue and Forecast, by End User
12.4.6.4. Market Revenue and Forecast, by Distribution Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Type
12.4.7.2. Market Revenue and Forecast, by Disease Type
12.4.7.3. Market Revenue and Forecast, by End User
12.4.7.4. Market Revenue and Forecast, by Distribution Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Treatment Type
12.4.8.2. Market Revenue and Forecast, by Disease Type
12.4.8.3. Market Revenue and Forecast, by End User
12.4.8.4. Market Revenue and Forecast, by Distribution Channel
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Type
12.5.2. Market Revenue and Forecast, by Disease Type
12.5.3. Market Revenue and Forecast, by End User
12.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Treatment Type
12.5.5.2. Market Revenue and Forecast, by Disease Type
12.5.5.3. Market Revenue and Forecast, by End User
12.5.5.4. Market Revenue and Forecast, by Distribution Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Treatment Type
12.5.6.2. Market Revenue and Forecast, by Disease Type
12.5.6.3. Market Revenue and Forecast, by End User
12.5.6.4. Market Revenue and Forecast, by Distribution Channel
13.1. Medtronic plc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. AbbVie Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Theravance Biopharma, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. ANI Pharmaceuticals, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Daewoong Pharmaceutical Co., Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Evoke Pharma Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AbbMed Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Cadila Healthcare Limited
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Teva Pharmaceutical Industries Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Evoke Pharma Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
